Find policies, billing codes, payers, states, and providers
Immunopharmacologic Monitoring of Therapeutic Serum Antibodies
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage for measurement of serum drug levels and anti‑drug antibodies for biologic therapies (primarily anti‑TNF agents, ustekinumab, vedolizumab, rituximab) with specific coverage decisions for inflammatory bowel disease versus other indications; applies to Oscar Health members and providers submitting reimbursement claims.
No material clinical or coverage changes in this revision.
Coverage Criteria for Therapeutic Drug and Anti-Drug Antibody Monitoring
IBD therapeutic drug/antibody monitoring
Covered when the stated conditions are met
Applies to anti-TNF agents, vedolizumab, ustekinumab
Non-IBD and other situations
Not covered when the following conditions are present
Examples listed in policy: spondyloarthritis, RA, psoriatic arthritis, psoriasis
List is explicit in policy; applies when situation not otherwise addressed
Consensus-based appropriate scenarios for TDM
Appropriate to order drug/antibody concentration testing in the following distinct scenarios as supported by consensus statements and guidelines:
Consensus 92% (12/13)
Consensus 100% (13/13)
Consensus 100% (13/13)
Consensus 100% (13/13)
Mixed consensus; detectable drug generally required but specific thresholds insufficient
TDM Coverage Criteria (consensus statements)
Consensus-based indications and principles for performing TDM (reactive and proactive) in IBD and related immune-mediated diseases
Testing for anti-TNF therapies outside of inflammatory bowel disease (IBD) is not supported by this policy. Drug and/or antibody concentration testing for anti‑TNF agents DOES NOT MEET CRITERIA for conditions such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis. Documented clinical context that indicates IBD is required to align with coverage criteria and reduce the risk of claim denial.
For IBD indications the policy explicitly allows testing (see IBD coverage criteria), but when ordering TDM for non‑IBD immune‑mediated diseases clinicians should be aware that evidence and guideline guidance differ by specialty and that testing for these other indications may not be covered.
Some guideline bodies have cautioned against routine adoption of ELISA kits for TNF inhibitor monitoring outside research contexts. The National Institute for Health and Clinical Excellence (NICE, 2016) stated that ELISA kits “show promise” but that there is currently insufficient evidence to recommend their routine adoption, and recommended their use primarily within research or data‑collection settings.
Similarly, guideline technical reviews and society statements note that proactive routine monitoring in quiescent IBD lacks consistent evidence of benefit and should not be universally applied; proactive testing strategies should be aligned with published guideline recommendations and study contexts.
The policy recognizes important evidence gaps for proactive therapeutic drug monitoring (TDM) of biologics other than anti‑TNF agents. Consensus statements agree that more data are needed to support routine proactive TDM for non‑anti‑TNF biologics, and current recommendations focus on selective use (for example, reactive TDM or post‑induction checks) rather than universal proactive schedules.
For vedolizumab and ustekinumab the policy notes emerging associations between drug levels and outcomes but explicitly states that these data are insufficient to define specific induction or maintenance target concentrations beyond confirming detectable drug.
The reference and publication‑history sections of the policy list supporting literature and guideline sources but do not state explicit coverage exclusions beyond those already included in the policy language. No separate or additional exclusionary statements are present in the referenced publication‑history sections.
Providers should rely on the policy’s Coverage Criteria and Not Medically Necessary sections for the operative coverage stance rather than expecting additional exclusions to appear in the reference lists.
Measurement of serum drug levels and/or anti‑drug antibodies for the drugs listed in the policy is considered not medically necessary when used in situations not specifically addressed by the coverage criteria. The policy lists specific agents (including adalimumab, certolizumab, etanercept, golimumab, infliximab and its biosimilars, rituximab, ustekinumab, and vedolizumab) and states that testing for these agents DOES NOT MEET CRITERIA outside of the defined IBD contexts or other expressly permitted scenarios.
When clinical indications are not explicitly covered (for example, non‑IBD presentations or unspecified contexts), providers should document the clinical justification and recognize that such testing may be denied as not medically necessary.
Routine proactive TDM for all unselected patients in clinical remission (quiescent IBD) is of uncertain benefit and is not uniformly recommended. Some guideline statements specifically advise against universal proactive monitoring in quiescent ulcerative colitis and emphasize targeted TDM for patients with active disease, at high risk of relapse, or when considering de‑escalation.
The policy aligns with guideline recommendations by supporting proactive TDM post‑induction and at least once during maintenance for anti‑TNF therapies, particularly in higher‑risk or more severely active patients, but it does not endorse routine, indiscriminate proactive testing in all patients in remission.
For vedolizumab and ustekinumab there is currently insufficient evidence to specify target induction and maintenance trough concentrations. Consensus language in the policy indicates that while detectable drug levels are generally required, specific numeric targets for induction and maintenance have not been established for these agents and therefore cannot be used as firm coverage thresholds.
As a result, testing for these agents may be used to confirm drug exposure or to aid clinical decision‑making in non‑routine situations, but the absence of validated target ranges limits the use of proactive TDM‑based dosing algorithms for vedolizumab and ustekinumab.
Although the policy cites an extensive evidence base and lists multiple references, the referenced sections do not contain explicit statements labeling particular tests or scenarios as categorically “not medically necessary” beyond the policy’s own Not Medically Necessary language. No additional explicit 'not medically necessary' statements are present in the publication history or reference listings.
Coverage determinations should therefore be made using the policy’s coverage and exclusion sections supported by the referenced literature, rather than expecting standalone NNM statements in the bibliography.
There are unaddressed situations in which measurement of serum drug levels and/or anti‑drug antibodies may be requested (for example, indications outside IBD, rare clinical scenarios, or agents where the policy provides limited guidance). In such cases the policy treats testing as not meeting criteria unless a covered scenario applies; clinicians should provide clear documentation of the clinical rationale when ordering tests that are not explicitly addressed.
When considering testing in unaddressed situations, providers should reference guidance cited in the policy (for example, NICE and ACG statements) and be prepared to justify testing as part of research, data collection, or a specific clinical management plan consistent with the available evidence.
Procedure Codes, Thresholds, and Test Identifiers
| 80145 | Adalimumab |
| 80230 | Infliximab |
| 80280 | Vedolizumab |
| 80299 | Quantitation of therapeutic drug, not elsewhere specified |
| 82397 | Chemiluminescent assay |
| 0514U | Immunoassay for quantitative determination of adalimumab (Procise ADL™) — proprietary assay (ProciseDx Inc.) |
| 0515U | Immunoassay for quantitative determination of infliximab (Procise IFXT™) — proprietary assay (ProciseDx Inc.) |
Provider Responsibilities, Prior Authorization, and Management Actions
Coverage for IBD testing
For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing for anti‑TNF agents, vedolizumab, or ustekinumab meets criteria when performed at the frequencies cited in the policy (examples include testing at the end of induction and at least once during maintenance; policy also allows testing “once every two weeks” in IBD when the stated conditions are met).
- Examples of endorsed timepoints: end of induction and at least once during maintenance for anti‑TNFs (consensus statements).
- Policy language: “For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti‑TNF therapies, vedolizumab therapy, or ustekinumab therapy MEETS CRITERIA.”
Align prior authorization to guideline indications
Prior authorization determinations and requests should align with guideline‑endorsed indications — principally reactive TDM for active IBD and consideration of testing at end of induction and at least once during maintenance for anti‑TNF agents as described by consensus and GI society guidance.
- AGA suggests reactive TDM in adults with active IBD treated with anti‑TNF agents; routine proactive monitoring in quiescent IBD is not generally recommended.
- ACG/consensus statements recommend testing at end of induction and at least once during maintenance for anti‑TNFs.
Procedure codes for TDM
Use the procedure and proprietary assay codes listed in the policy when submitting claims or prior authorization requests for immunopharmacologic monitoring.
Prior authorization
The publication‑history and reference sections do not specify any additional prior authorization requirements applicable to this policy.
- Publication history records governance approval on 06/16/2026.
Clinical approach to therapy adjustment
Typical clinical practice is to adjust or switch bDMARDs only when clinical evidence shows remission or low disease activity is not achieved or maintained; concomitant immunomodulators (e.g., methotrexate or thiopurines) may be used to reduce immunogenicity.
- Policy: adjust or switch bDMARDs when there is clinical evidence that remission or low disease activity is not achieved or maintained.
- ACG recommends considering combination therapy with immunomodulators in patients with prior anti‑TNF antibodies to reduce immunogenicity.
Therapy change recommended for high‑titer antibodies
When TDM demonstrates absent drug with high‑titer anti‑drug antibodies (especially for infliximab), switching therapy is recommended rather than dose escalation; low‑level antibodies may be managed with treatment optimization.
- High‑titer antibodies prompting secondary loss of response should lead to switching therapy rather than dose escalation.
- Low‑titer antibodies (e.g., <10 U/mL by HMSA for infliximab) can potentially be overcome by dose optimization or adding an immunomodulator.
Management after antibody‑mediated loss of response
For secondary loss of response to an anti‑TNF caused by high‑titer anti‑drug antibodies, do not dose‑escalate — instead change to an alternative therapy; if switching within class after antibody‑mediated loss, add an immunomodulator to the subsequent anti‑TNF regimen.
- Policy statement: patients with secondary loss of response due to high‑titer antibodies should be switched (within‑class or out‑of‑class).
- When switching within class after antibody‑mediated loss, add an immunomodulator to the new anti‑TNF therapy.
Step therapy considerations
The literature compares proactive versus reactive TDM and standard therapy, but the policy does not establish explicit payer step‑therapy rules — payers should not infer additional mandatory step requirements beyond the published guidance.
- Referenced studies evaluate proactive vs reactive TDM (e.g., cost‑effectiveness and outcomes) but no explicit payer step‑therapy mandates are stated in the policy.
Billing and documentation responsibility
Providers are responsible for submitting accurate documentation and using appropriate industry‑standard coding when billing for TDM services; failure to follow coding/billing guidelines may result in denial or recoupment.
- Policy requires coding per standard sources (CPT®, HCPCS, ICD‑10, CMS guidance).
- Claims may be denied or recouped if appropriate coding/billing guidelines or current reimbursement policies are not followed.
Document disease activity and reason for testing
Document the clinical context when ordering TDM — specify disease activity (active vs quiescent), whether testing is for primary nonresponse, secondary loss of response, or post‑induction assessment to align with guideline recommendations.
- AGA/ACG and consensus statements endorse reactive testing for active disease and testing at end of induction; documentation should state the reason for testing.
- Include status (e.g., primary nonresponse, secondary loss of response, post‑induction) in the medical record and submission materials.
Laboratory validation
Laboratory‑developed tests (LDTs) used for TDM are regulated under CLIA as high‑complexity tests; laboratories must validate and perform these assays in‑house per CMS/CLIA requirements.
- LDTs are not FDA‑cleared/approved for clinical use and must be validated and performed in‑house; regulated by CMS under CLIA '88 as high‑complexity tests.
Limited evidence may lead to non‑coverage
Some proactive TDM uses and testing for indications other than IBD (e.g., RA, psoriatic arthritis, spondyloarthritis, psoriasis) are less supported by the policy and may not meet criteria — ordering TDM outside IBD risks denial.
- Policy: testing for conditions other than IBD does not meet criteria (examples listed include spondyloarthritis, RA, psoriatic arthritis, psoriasis).
- Guidance: AGA/ACG note limited support for routine proactive monitoring in quiescent IBD and variable evidence for non‑IBD indications.
Conflict with government policy
If there is any conflict between this policy and applicable government coverage (LCDs/NCDs or state Medicaid rules), follow the government policy — failure to do so may result in denial or use of the government policy to adjudicate coverage.
- Policy disclaimer: government policy (LCD/NCD/state) supersedes this policy when conflicts exist; providers should check applicable Medicare/Medicaid guidance.
Claim denial and recoupment risk
Claims for TDM services may be denied or recouped if appropriate coding, billing, or current reimbursement policies are not followed; ensure claims match documented medical necessity and selected procedure codes.
- Policy warning: we may deny the claim and/or recoup payment if coding/billing guidelines or reimbursement policies are not followed.
- Accurate documentation and use of listed CPT/HCPCS/proprietary codes support proper claim adjudication.
Publication history and governance
Publication history documents governance approval on 06/16/2026; no additional procedural documentation requirements are specified in the publication‑history section.
- Publication History: Original Documentation; Governance Approved 06/16/2026.
Background and Rationale
Anti-drug antibodies can reduce biologic efficacy and promote adverse immune effects, which is the clinical rationale for targeted monitoring. The policy frames therapeutic drug monitoring (measurement of trough drug levels and anti-drug antibodies) as a tool to manage primary nonresponse, confirmed secondary loss of response, and to inform decisions about dose optimization or switching therapy—particularly for anti-TNF agents where the evidence and guidance are strongest.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.